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Abstract 
Background: Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease. Complement com‑
ponent 4 (C4) has be proved to play a role in pathogenesis of SLE. In the present study, we investigated the effect of 
C4 on T cells differentiation.
Methods: Thirty SLE patients were included in this study. CD4+ T cells were isolated from healthy subjects, and 
dendritic cells (DCs) were isolated from healthy subjects or SLE patients. C4 was supplemented to co‑incubate with T 
cells and DCs.
Results: Serum C4 concentration was positively correlated with regulatory T cell (Treg) percentage (R2 = 0.5907, 
p < 0.001) and TGFβ concentration (R2 = 0.5641, p < 0.001) in SLE patients. Different concentrations of C4 had no 
effect on T cells differentiation. Co‑incubated T cells with DCs and C4 for 7 days, the Treg percentage and TGF‑β con‑
centration were significantly elevated. In addition, pre‑treated DCs (from healthy subjects or SLE patients) with C4 and 
then co‑incubated with T cells, the increases of Treg percentage and TGF‑β concentration were also observed.
Conclusion: C4 takes part in T cells differentiation to Treg cells via DCs.
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Background
Systemic lupus erythematosus (SLE), a severe multisys-
tem autoimmune disease, is characterized by a loss of 
immune tolerance to self-antigens (Ags), which results 
in the persistent production of pathogenic autoantibod-
ies, activation of lymphocyte and release of inflammatory 
mediators [1]. Many factors including genetic, environ-
mental and hormonal contribute to initiate and drive SLE 
pathogenesis [2]. However, the exact pathogenic mecha-
nisms remain to be elucidated.
Regulatory T cells (Tregs) are involved in inhibition 
process of CD4+ Th cells activation, cytotoxic CD8+ 
T cells differentiation and B cell activation [3–5]. The 
definitive role of Treg cells in SLE remains not fully clear. 
In SLE patients, the reduced number and function of 
CD4+CD25 Foxp3 Tregs have been observed [6]. The 
deficiencies of Tregs might contribute to the breakdown 
of self-tolerance and the development of the autoimmune 
response in SLE patients [7].
Complement component 4 (C4), a protein involved in 
complement system, takes part in multiple aspects of the 
immune system [8]. It has also be shown that comple-
ment system is implicated in pathogenesis of SLE and 
has important protective functions in SLE [9, 10]. SLE 
patients have decreased C4 copy number and serum C4 
concentration [11], and low copy number of C4 is iden-
tified to be a risk factor for SLE susceptibility [12]. The 
mechanisms of the link between abnormal complement 
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system and SLE or SLE-like diseases have been partly 
proposed, including impaired clearance of immune 
complexes and apoptotic cells, abnormal development 
of B cell self-tolerance [8, 13]. In a recent study, it was 
shown that knockout C4 complement gene mice had a 
decreased frequency of Treg cells [14], which implies 
that C4 complement can promote differentiation of 
T lymphocyte to Tregs. C4-derived peptide has been 
demonstrated to inhibit Th1 cytokine production [15]. 
However, very few literatures have been emerging to 
elaborate the effects of C4 on Treg cells. Transforming 
growth factor-beta (TGF-β) is critical for the develop-
ment and differentiation of Tregs, and it is an important 
indicator for reflecting the function and stabilization of 
Tregs [16]. In present study, we investigated whether C4 
participated in T cells differentiation and the potential 
mechanism was also explored.
Methods
Subjects
Thirty SLE patients, with 10 female and 20 male, regu-
larly followed up at the Second Affiliated Hospital of 
Anhui Medical University (from November 2012 to June 
2014) were included in this study. The human study was 
approved by Ethics Committee of the Anhui Medical 
University and written informed consents were obtained 
from all patients. The clinical information including 
age, gender, duration of disease and concentrations of 
α-globulin, β-globulin, IgG, IgA and IgM were collected. 
The concentrations of α-globulin, β-globulin, IgG, IgA 
and IgM were detected.
Isolation and culture of T cells
The T cells were isolated from peripheral blood mono-
nuclear cells (PBMCs) of healthy subjects. PBMCs were 
isolated by Ficoll density gradient centrifugation and col-
lected to culture in RPMI1640 medium (Gibco, USA). 
Immuno-magnetic beads (Miltenyi Biotec, Germany) 
were used to isolate CD4+ T cells according to the man-
ufacturer’s instructions. The obtained T cells were cul-
tured in RPIM1640 medium containing 10 % fetal bovine 
serum (Gibco, USA), penicillin–streptomycin (100  IU/
ml and 100 μg/ml, Sigma, USA) and 2 mM l-glutamine 
(Sigma, USA). In addition, different concentrations (0, 
250, 500 and 1000  μg/ml) of C4 were supplemented in 
medium to co-incubate with T cells for 7 days.
Isolation and culture of dendritic cells
The dendritic cells (DCs) were also isolated from periph-
eral blood of healthy subjects or SLE patients with C4 
number <4 copies. Mononuclear cells were collected 
from the blood supernatant. RPMI1640 medium, con-
taining 10  % autoserum (Gibco, USA) and 50  ng/ml 
rhIL-7 (R&D Systems, USA), was used to culture and 
induce differentiation of mononuclear cells for 24  h. In 
some experiments, 500  μg/ml complement C4 (Sigma-
Aldrich, USA) was pre-treated with DCs for 48 h. Then 
C4 treated DCs were co-cultured with 2  ×  104 freshly 
isolated CD4+ T cells in round-bottom 96-well cul-
ture plates for 7  days. In other experiments, DCs co-
incubated with 2 × 104 freshly isolated CD4+ T cells in 
RPMI1640 medium containing 500  μg/ml complement 
C4 for 7 days.
Detection of serum complement C4 and TGFβ 
concentrations
The isolated serum from patients was stored at 80  °C. 
The serum C4 level was measured using a human ELISA 
kit (DRG-international, Germany). The TGF-β concen-
trations were also determined using commercial ELISA 
kit (R&D Systems, USA). All the experimental opera-
tions were performed according to the manufacturer’s 
instructions.
Flow cytometry
T lymphocyte subsets were analyzed by flow cytometry 
(Beckman Coulter, USA). The cells were stained using 
PerCP-Cy5.5-labeled anti-human CD3 (eBioscience, 
USA) and fluorescein isothiocyanate (FITC)-labeled anti-
human CD8 (eBioscience, USA). Treg cells were identi-
fied using FITC-labeled anti-human CD4 (eBioscience, 
USA). The various T lymphocyte subsets were calculated 
using the antibody signals of the specific proteins.
Real‑time quantitative PCR
FlexiGene DNA Kit (Qiagen, Germany) was used 
to extract genomic DNA from human whole blood. 
TaqMan® Genotyping Master Mix (Applied Biosystems, 
USA) was used to quantify gene expression, with RNaseP 
(Applied Biosystems, USA) serving as reference genome. 
The C4 copy number was analyzed by CopyCaller™ 
Software.
The total mRNA of T cells was extracted with RNe-
asy kit (Invitrogen, USA). cDNA was synthesized using 
ImProm-II™ Reverse Transcription System (Promega, 
USA). The mRNA expression of FOXP3 was quanti-
fied by Applied Biosystems 7500 Real-Time PCR System 
(Applied Biosystems, USA) with Power SYBR® Green 
PCR Master Mix (Applied Biosystems, USA). The FOXP3 
primers are as follows: forward 5′-AGGCTTCATCTG 
TGGCATCAT-3′; reverse 5′-CTTGCGGAACTCCAGC 
TCAT-3′. β-actin serves as the control gene to normalize 
the quantification of FOXP3. The primers of β-actin are as 
follows: forward 5′-CTCCATCCTGGCCTCGCTGT-3′; 
reverse 5′-GCTGTCACCTTCACCGTTCC-3′. Ct 
method was used to analyze the relative gene expression.
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Statistical method
The results are given as mean ±  standard error (SEM). 
Statistical significance among three experimental groups 
was assessed by ANOVO, and the difference between 
two experimental groups was assessed by independent-
samples T test. Correlations between plasma comple-
ment C4 and Treg percentage/TGF-β were determined 
by Pearson correlation coefficient. All statistical analyses 
were performed using the SPSS 17.0. Significance was 
assumed at a p level of less than 5 %.
Results
Summary of study group characteristics and observed 
expressions
As shown in Table 1, the patients with C4 copy numbers 
<4 were matched with the patients with C4 copy num-
bers  =  4 or C4 copy numbers >4 for sample number, 
and there were no significant differences in age, gender 
and duration of disease among three groups. The levels 
of α-globulin and γ-globulin in subjects with C4 copy 
numbers >4 were significantly decreased compared with 
subjects with C4 copy numbers <4. The concentrations 
of IgG, IgA and IgM were decreased with the increasing 
of C4 copy numbers. In addition, serum complement C4 
concentrations were elevated with the increasing of C4 
copy numbers.
Correlation of serum complement C4 concentration 
and Treg percentage
The serum Treg percentages of SLE patients were 
detected. As shown in Fig.  1a, the values of Treg per-
centage in patients with C4 < 4 copies, = 4 copies and >4 
copies respectively were 0.62, 0.79 and 1.00. The Fig. 1b, 
c showed that peripheral serum C4 concentration was 
positively correlated with Treg percentage (R2 = 0.5907, 
p  <  0.001) and TGFβ concentration (R2  =  0.5641, 
p < 0.001) respectively in SLE patients.
The effect of complement C4 on differentiation of T 
lymphocytes
Administrated T cells with complement C4 of dif-
ferent concentrations (DC:T  =  1: 6) for 7  days, the 
CD4+CD25+FOXP3+Treg percentage was determined 
by Flow Cytometer. The results showed that there was 
no difference in CD4+CD25+FOXP3+Treg percentage 
between cells with or without complement C4 treatment 
(Fig.  2a, b). The differences of Foxp3 mRNA expression 
and TGFβ concentrations were not observed in cells 
treated with complement C4 of different dosages (Fig. 2c, 
d).
Complement C4 promotes T lymphocytes differentiation 
via DCs in healthy subjects
Isolated DCs from healthy subjects. Pre-incubated T 
lymphocytes with the DCs for 24  h, and then supple-
mented with 500 μg/ml complement C4 for 7 days. The 
results of Flow Cytometer showed that complement 
C4 significantly increased CD4+CD25+FOXP3+Treg 
percentage in cells pretreated with DCs. However, the 
effect was reversed by interference of CR1, a receptor of 
complement C4 (Fig. 3a, b). The concentration of TGFβ 
was also increased by complement C4 in T lymphocytes 
pre-incubated with DCs, and supplement of siRNA-CR1 
decreased TGFβ concentration.
On the other hand, treated DCs (from healthy sub-
jects) with 500 μg/ml complement C4 for 48 h, and then 
incubated with T lymphocytes for another 7  days. The 
data also shown that CD4+CD25+FOXP3+Treg cells 
Table 1 Summary of study group characteristics and observed expressions
Data are presented as the mean ± standard error of mean
Ig immunoglobulin
* p < 0.05, vs group (C4 copy numbers <4)
# p < 0.05, vs group (C4 copy numbers = 4)
Variable C4 copy numbers <4 C4 copy numbers = 4 C4 copy numbers >4
Number of samples (n) 10 10 10
Age (years) 52.4 ± 6.8 53.3 ± 4.9 51.8 ± 8.4
Gender, male/female (n) 7/3 6/4 7/3
Duration of disease (years) 3.5 ± 1.3 2.9 ± 0.9 2.7 ± 1.5
α‑Globulin (g/cl) 0.72 ± 0.07 0.69 ± 0.05 0.59 ± 0.06*#
γ‑Globulin (g/cl) 0.82 ± 0.11 0.71 ± 0.09* 0.70 ± 0.07*
IgG (mg/cl) 1459 ± 104 1302 ± 58* 1219 ± 49*#
IgA (mg/cl) 31.8 ± 4.9 26.5 ± 6.1* 20.6 ± 3.9*#
IgM (mg/cl) 32.5 ± 5.3 25.2 ± 4.18* 19.4 ± 2.0*#
Serum complement C4 (g/L) 49.3 ± 7.9 78.4 ± 12.3* 110.3 ± 15.2*#
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percentage (Fig. 4a, b) and TGFβ concentration (Fig. 4c) 
were markedly elevated by DCs exposed to complement 
C4.
Complement C4 promotes T lymphocytes differentiation 
via DCs in SEL patients
Isolated DCs from SLE patients with C4 copy num-
bers <4. DCs were pre-treated with complement C4 
before co-incubated with T lymphocytes. It was also 
observed that complement C4 significantly increased 
CD4+CD25+FOXP3+Treg cells percentage (Fig.  5a, b) 
and TGFβ concentration (Fig. 5c) via DCs.
Discussion
The complement system, exists in tissues and serum, is 
a part of immune system that helps or complements the 
ability of antibodies and phagocytic cells to clear patho-
gens from the organism [17]. C4 is one important com-
ponent of complement system. The role of complement 
in SLE is complex. On one hand, complement is inte-
gral in the inflammatory reaction in SLE that results in 
tissue and organ damage. On another hand, the defi-
ciency of complement is a strong risk factor to promote 
the development of SLE [8, 11, 13, 18]. However, it has 
been widely considered that complement system plays a 
protective role against the progression of SLE and other 
autoimmune disorders in normal subjects. In the present 
study, we found serum complement C4 concentrations 
were elevated with the increasing of C4 copy numbers. 
Waste disposal hypothesis, impaired immune complex 
processing and dysregulation of cytokines are proposed 
to explain the causal link between SLE and early classical 
pathway complement deficiencies [8, 19, 20]. While the 
exact mechanisms remain to be elucidated. We observed 
serum complement C4 in SLE patients was positively 
correlated with Treg percentage. The further studies con-
firmed that complement C4 modulated T cells differen-
tiation by mediating DCs.
Fig. 1 The correlation between serum complement C4 concentration and Treg percentage. a The Treg percentage was detected by flow cytom‑
etry; n = 10; the data were expressed as mean ± standard error; *p < 0.05; **p < 0.01. b Spearman correlation was used to evaluate the relationship 
between Treg percentage and C4 concentration. c Spearman correlation was used to evaluate the relationship between Treg percentage and TGFβ 
concentration
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Fig. 2 The effect of complement C4 on differentiation of T lymphocytes. a Flow Cytometer was used to determine the CD4+CD25+FOXP3+Treg 
percentage. b The statistical result of Flow Cytometer was shown. c Real‑time PCR was used to quantify Foxp3 relative mRNA expression. d TGFβ 
concentration of cells was determined by ELISA kit
Fig. 3 Complement C4 promotes T lymphocytes differentiation via DCs. Pre‑incubated T lymphocytes with DCs for 48 h, and then 500 μg/ml com‑
plement C4 was supplemented for 7 days. a Flow Cytometer was used to determine the CD4+CD25+FOXP3+Treg percentage. b The statistical 
result of Flow Cytometer was shown. c TGFβ concentration of cells was determined by ELISA kit. **p < 0.01 vs control; #p < 0.05 vs C4 group
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Tregs, commonly known as suppressor T cells, are a 
component of the immune system that suppress immune 
responses of other cells and prevent the onset of aber-
rant self-immune response [21, 22]. Recently, Tregs have 
been assessed in SEL patients [23–25]. The decreased 
Tregs number and impaired function are observed in 
SLE patients [26, 27]. However, it remains unknown 
whether Tregs are necessary for the pathophysiology of 
SLE, which is a very important topic for us and other 
investigators. In this study, the value of Treg percentage 
was elevated with the increase of serum C4 copy num-
ber in patients with SLE, which implied a close rela-
tionship between Treg cells and complement C4 level. 
However, administrated T cells with different concentra-
tions of complement C4, no significant differences were 
observed in CD4+CD25+FOXP3+Treg population, 
FOXP3 mRNA and TGFβ concentrations compared with 
T cells without the treatment of complement C4. FOXP3 
appears to function as a master regulator in the devel-
opment and function of Treg cells [28]. TGFβ is known 
to be critical for the activation of Treg cells and the 
expression of FOXP3 [29], and it has been reported that 
low levels of TGFβ1 correlate with increased SLE disease 
activity [30]. The above results suggest that complement 
C4 is associated with Treg cells, but the role of comple-
ment C4 on Treg cells is not conducted directly.
There are two ways to have functions on Treg cells by 
complement, which including direct action and indirect 
action. William et  al. demonstrated that targeting C3a/
C3aR and C5a/C5aR interactions could facilitate iTreg-
mediated tolerance to alloantigens in humans [31]. Our 
in  vitro study demonstrated that it was not through 
direct action in C4 induced Treg cells differentiation. 
Sacks et  al. found C5aR activates naïve CD4+ Th cells 
to undergo differentiation not only to IL-17 producing T 
helper (Th17) cells but also to Treg via a TGFβ dependent 
pathway [32]. Recent studies form human and animals 
provide the evidences for the role of IL-17 and Th17 cells 
in the pathogenesis of SLE [33, 34]. Therefore, we sup-
posed C4 maybe have effect on promoting Treg cells dif-
ferentiation via DCs. We found that T cells, co-incubated 
with DCs and then administrated with complement C4, 
Fig. 4 Pretreating DCs from healthy subjects with complement C4 promotes T lymphocytes differentiation. Pre‑incubated DCs (from healthy 
subjects) with 500 μg/ml complement C4 for 48 h, and then incubated with T lymphocytes for 7 days. a Flow Cytometer was used to determine 
the CD4+CD25+FOXP3+Treg percentage. b The statistical result of Flow Cytometer was shown. c TGFβ concentration of cells was determined by 
ELISA kit; **p < 0.01 vs control
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had a higher level of CD4+CD25+FOXP3+Treg per-
centage and TGFβ concentration. In addition, DCs pre-
treated with complement C4 before co-incubated with T 
cells, the similar results were observed. These data sug-
gested that DCs took part in mediating T cells differenti-
ation induced by complement C4. Complement receptor 
type 1 (CR1), the receptor of complement C4, serves as 
the main system for processing and clearance of comple-
ment opsonized immune complexes [35]. Inhibiting CR1 
of T cells, which were co-incubated with DCs and then 
administrated with C4, showed the decreased levels of 
CD4+CD25+FOXP3+Treg percentage and TGFβ con-
centration. The data confirmed that C4 mediated the T 
cells differentiation.
In summary, we found C4 takes part in T cells differ-
entiation to Treg cells via DCs, suggesting that Treg cells 
serve as the target therapy in preventing or controlling 
immune-mediated inflammatory disorders. Knowledge 
about Tregs and C4 and other regulatory cytokines pro-
vides new insights in the pathogenesis of SLE. The new 
lines of investigation for SLE treatment concerning Tregs 
and C4 will be opened in the near future.
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Fig. 5 Pretreating DCs from SLE patients with C4 copy numbers <4 with complement C4 promotes T lymphocytes differentiation. Pre‑incubated 
DCs (from SLE patients with C4 copy numbers <4) with 500 μg/ml complement C4 for 48 h, and then incubated with T lymphocytes for 7 days. a 
Flow Cytometer was used to determine the CD4+CD25+FOXP3+Treg percentage; b the statistical result of Flow Cytometer was shown; c TGFβ 
concentration of cells was determined by ELISA kit; **p < 0.01 vs control
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